Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

NCT00116610 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: picoplatin

Sponsor

Poniard Pharmaceuticals